alexa Novel Nicotinic Receptor Agonist Reduces Hyperalgesia a
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Novel Nicotinic Receptor Agonist Reduces Hyperalgesia and Allodynia of Neuropathic Pain in Diabetic Rats

Roberto C Debom1,2, Margarete M Trachez3,4, Gisele Zapata Sudo4*, Jaqueline S da Silva4, Kesley M Oliveira2, Ariel L Garcia2, Lidiane M Godoy2, Ogari C Pacheco2 and Roberto T Sudo1,4

1Programa de Pós-graduação em Medicina (Cirurgia Geral), Universidade Federal de Rio de Janeiro, Rio de Janeiro, Brazil

2Cristália Produtos Químicos e Farmacêuticos Ltda, Itapira, São Paulo, Brazil

3Disciplina de Anestesiologia, Universidade Federal Fluminense, Rio de Janeiro, Brazil

4Programa de Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

*Corresponding Author:
Gisele Zapata-Sudo, M.D., Ph.D.
Universidade Federal do Rio de Janeiro
Centro de Ciências da Saúde
Instituto de Ciências Biomédicas
Bloco J, Sala 14, Rio de Janeiro, RJ, Brazil, 21941-590
Tel: 55-21-25626478
Email: [email protected]

Received date: May 06, 2014; Accepted date: June 19, 2014; Published date: June 27, 2014

Citation: Debom RC, Trachez MM, Sudo GZ, S da Silva J, Oliveira KM, et al. (2014) Novel Nicotinic Receptor Agonist Reduces Hyperalgesia and Allodynia of Neuropathic Pain in Diabetic Rats. J Diabetes Metab 5:396. doi:10.4172/2155-6156.1000396

Copyright: © 2014 Debom RC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

 

Abstract

Diabetic Peripheral Neuropathic Pain (DPNP) has been attributed to abnormal glucose metabolism and oxidative stress. It is among the most common consequence of chronic diabetes and is treated with antiepileptic compounds, antidepressants, and opioids. However, many patients with DPNP experience lack of treatment efficacy and/or adverse secondary effects that impair quality of life. Here we report the identification of a novel agonist targeting neuronal nicotinic Acetylcholine Receptors (nAChRs) that may alleviate neuropathic pain. A new pyrazole analogue, Cris-104, has been observed to produce antinociceptive activity in acute and chronic pain models. In the present study, Cris-104 effects on thermal hyperalgesia and mechanical allodynia were evaluated in a rat DPNP model. Oral administration of Cris-104 (35 mg.kg-1.day-1 for 7 days) induced antinociception as evidenced by reductions in thermal hyperalgesia and mechanical allodynia in DPNP rats. The mechanism of antinociception cannot be attributed to a diabetes-alleviating effect because blood glucose levels were not reduced significantly by the treatment. The analgesia could be mediated by activation of nAChRs since Cris-104 is a specific ligand for the nAChR. In conclusion, Cris-104 is a compound with potential to be used as a pain reliever in patients with DPNP.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords